We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

261 hedge funds and large institutions have $3.6B invested in Bio-Rad Laboratories Class A in 2016 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 90 increasing their positions, 81 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

775% more call options, than puts

Call options by funds: $6.39M | Put options by funds: $730K

85% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 27

60% more funds holding in top 10

Funds holding in top 10: 58 (+3)

18% more capital invested

Capital invested by funds: $3.05B → $3.6B (+$548M)

11% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 81

8% more funds holding

Funds holding: 241261 (+20)

2.2% more ownership

Funds ownership: 78.6%80.8% (+2.2%)

Holders
261
Holders Change
+20
Holders Change %
+8.3%
% of All Funds
6.53%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.2%
New
50
Increased
90
Reduced
81
Closed
27
Calls
$6.39M
Puts
$730K
Net Calls
+$5.66M
Net Calls Change
+$533K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
201
Americafirst Capital Management
California
$255K -$1.6M -9,360 -87%
GT
202
Glenmede Trust
Pennsylvania
$237K
PM
203
Parametrica Management
Hong Kong
$232K +$217K +1,274 New
QSS
204
Quantitative Systematic Strategies
Florida
$223K -$969K -5,684 -82%
PAM
205
Panagora Asset Management
Massachusetts
$218K
ACI
206
AMP Capital Investors
Australia
$213K +$198K +1,160 New
EP
207
Elkfork Partners
Oregon
$211K +$197K +1,156 New
Allianz Asset Management
208
Allianz Asset Management
Germany
$203K -$709K -4,156 -79%
AIM
209
Alambic Investment Management
California
$201K +$188K +1,100 New
Creative Planning
210
Creative Planning
Kansas
$191K +$6.82K +40 +4%
LTFS
211
Ladenburg Thalmann Financial Services
Florida
$176K +$11.1K +65 +7%
GHCM
212
Glen Harbor Capital Management
California
$174K +$162K +952 New
Barclays
213
Barclays
United Kingdom
$168K +$63.1K +370 +67%
RCM
214
Riverhead Capital Management
Delaware
$164K +$17K +100 +13%
NIMI
215
Natixis Investment Managers International
France
$164K +$153K +900 New
HNB
216
Huntington National Bank
Ohio
$163K -$67.3K -395 -31%
TRCT
217
Tower Research Capital (TRC)
New York
$161K +$38.5K +226 +34%
PHK
218
Point72 Hong Kong
Hong Kong
$159K +$149K +874 New
AG
219
Advisor Group
Arizona
$150K +$9.89K +58 +8%
MCIM
220
Meadow Creek Investment Management
Georgia
$136K +$128K +748 New
Zurich Cantonal Bank
221
Zurich Cantonal Bank
Switzerland
$132K
CSS
222
Cubist Systematic Strategies
Connecticut
$120K -$357K -2,093 -76%
JP Morgan Chase
223
JP Morgan Chase
New York
$118K -$811K -4,756 -88%
FCM
224
Flinton Capital Management
Pennsylvania
$99K +$92.7K +544 New
SF
225
Synovus Financial
Georgia
$78K +$76K +446 New

BIO Hedge Fund Activity: Q4 2016 in Review

261 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2016, worth a combined $3.6B — up 18% from $3.05B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new BIO positions and 27 closed out — a net gain of 23 holders — while 90 added to existing stakes and 81 trimmed.

The largest buyer was TimesSquare Capital Management, opening a new position worth an estimated $89M. The largest seller was Credit Suisse, cutting an estimated $51.8M.

  • 261 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2016, up from 241 in Q3 2016.
  • Funds reported $3.6B of Bio-Rad Laboratories Class A stock for Q4 2016, up 18% quarter-over-quarter.
  • 50 funds opened new Bio-Rad Laboratories Class A positions in Q4 2016 and 27 closed out, a net change of +23 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q4 2016 was TimesSquare Capital Management, an estimated $89M added.
  • The largest Bio-Rad Laboratories Class A seller in Q4 2016 was Credit Suisse, an estimated $51.8M sold.

Based on aggregated 13F filings for Q4 2016.